The calcium-sensing receptor (CaSR) is the molecule that lets the body "read" extracellular ionized calcium and act on it in real time. It is a class C G-protein-coupled receptor — often described as the body's calciostat — most highly expressed on parathyroid chief cells and along the nephron, but also present in intestine, bone, breast epithelium, and pancreatic islets. Its job is deceptively simple: when extracellular calcium rises, CaSR activation suppresses parathyroid hormone (PTH) secretion and reduces renal calcium reabsorption; when calcium falls, the brakes come off and PTH restores it. The questions researchers and clinicians most often type into a search bar are concrete rather than textbook: what does a CaSR mutation do, why does familial hypercalcemia come with low urine calcium, how do you separate it from primary hyperparathyroidism, and — the practical one — what does a calcium-to-creatinine clearance ratio actually tell you? The receptor also threads through cancer biology and intestinal ion transport, which is why CaSR traffic has stayed steady even as the field has matured.

Browse More CaSR Products

The Calcium Sensing Receptor: A Class C GPCR Calciostat

CaSR functions as a homodimer. Each subunit carries a large extracellular venus flytrap domain (VFT) that opens and closes around its ligand, a cysteine-rich region, and seven transmembrane helices coupled to intracellular signaling machinery. The physiological trigger is extracellular ionized calcium, with a half-maximal activation concentration (the "set point") of roughly 1.25 mM — the level that defines normocalcemia in adults. But calcium is not the only ligand: magnesium acts as an endogenous co-activator, and aromatic L-amino acids such as L-phenylalanine and L-tryptophan derivatives sharpen the receptor's response through positive cooperativity. A 2016 structural study resolved the human extracellular domain bound to magnesium and a tryptophan-derived co-agonist, showing how the hinge between the two VFT subdomains integrates metal-ion and amino-acid signals into a single activation state.

On activation, CaSR engages heterotrimeric G proteins. The dominant arms are Gq/11 — driving phospholipase C, inositol trisphosphate, intracellular calcium release, and ERK/MAPK phosphorylation — and Gi/o, which lowers cyclic AMP; β-arrestin scaffolding adds a layer of biased, non-canonical signaling. In parathyroid chief cells the net effect is inhibition of PTH synthesis, secretion, and parathyroid cell proliferation. Along the cortical thick ascending limb and distal convoluted tubule the same receptor lowers paracellular calcium permeability, so activating it promotes calciuria. It also stimulates calcitonin release and modulates 1α-hydroxylase in the proximal tubule, nudging 1,25-dihydroxyvitamin D synthesis. This is why any single "calcium result" has to be interpreted against the hormone and urine context — the receptor is only one node in a closed feedback loop.

Figure 1. Model of activation and allosteric modulation of CaSR. (Source: Makita N, et al. 2019)

Key Molecules in the CaSR Axis

Calcium-Sensing Receptor (CaSR / CASR gene)

The receptor itself is the anchor of the axis. Germline variants in CASR shift the calcium set point: loss-of-function pushes it right (more calcium needed to suppress PTH), gain-of-function pushes it left. Protein-level detection (immunohistochemistry, Western blot, sandwich ELISA) reports how much receptor is present, but it cannot by itself reveal whether a given variant is hyper- or hypo-sensitive — that requires a functional assay. For translational studies the most informative readout is therefore the set point, measured as the extracellular calcium concentration that half-maximally suppresses PTH or half-maximally triggers an intracellular signal in a cellular assay.

Parathyroid Hormone (PTH) and PTHrP

PTH is the effector CaSR controls. The clinically used assay targets intact PTH (1–84), and in malignancy PTH-related peptide (PTHrP) is the parallel driver of humoral hypercalcemia. Interpreting PTH against calcium is the essence of CaSR diagnostics: inactivating-receptor disease shows inappropriately normal or high PTH for the calcium level, whereas a correctly suppressed PTH in hypercalcemia points away from parathyroid causes. Assay choice matters — some platforms detect only intact PTH while others capture longer fragments — so the same sample can read differently across methods, a frequent source of confusing results.

Fibroblast Growth Factor 23 (FGF23)

FGF23 is the phosphatonin made chiefly by osteocytes. It suppresses renal 1α-hydroxylase (lowering 1,25-dihydroxyvitamin D) and phosphate reabsorption, and its relationship to the CaSR axis is most visible in chronic kidney disease, where falling kidney function, rising FGF23, and secondary CaSR down-regulation in the parathyroid converge to drive secondary hyperparathyroidism. Measuring FGF23 together with intact PTH and 1,25(OH)2D captures the phosphate–vitamin-D–calcium crosstalk that a calcium value alone hides.

1,25-Dihydroxyvitamin D (Calcitriol)

The active vitamin D metabolite sits downstream of PTH and feeds back to dampen PTH secretion. It is the reason calcium and vitamin D status must be read together: hypovitaminosis D raises PTH independently of CaSR genotype, and correcting it can normalize borderline biochemistry. Quantification is typically by competitive ELISA or LC-MS, and the result reframes whether a high PTH is "primary," "secondary," or simply nutritional.

G Protein Subunits Gq/11 (GNA11) and Gi, plus AP2S1

These are the transducers CaSR hands its signal to, and they are not just black boxes. Germline variants in GNA11 and in AP2S1 — a clathrin-adaptor protein that traffics CaSR — cause familial hypocalciuric hypercalcemia types 2 and 3, phenocopies of CASR-inactivating disease because the receptor is never properly activated or delivered to the membrane. Naming them matters clinically: the biochemistry looks identical to CaSR disease, but the gene to sequence is different. For functional work, selective Gq versus Gi readouts disentangle which limb a variant has weakened.

Magnesium (Mg²⁺)

Magnesium is the often-overlooked endogenous CaSR agonist. In the parathyroid it modulates set-point sensitivity; in intestinal epithelium a 2024 investigation showed physiological luminal Mg²⁺ activates CaSR/Gq signaling to suppress cyclic-nucleotide-driven chloride secretion, pointing to an antisecretory role in secretory diarrhea. Serum magnesium therefore belongs in any serious CaSR workup, because low Mg²⁺ can blunt receptor responsiveness and mimic or mask a set-point defect.

When CaSR Goes Wrong: From Benign to Malignant

CaSR disease is best understood as a set-point disorder. In familial hypocalciuric hypercalcemia (FHH), inactivating variants in CASR — or, less often, GNA11 or AP2S1 — right-shift the set point so the body "thinks" normal calcium is too low, driving mild-to-moderate hypercalcemia with paradoxically low urinary calcium (hypocalciuria). The diagnostic wedge against primary hyperparathyroidism is the calcium-to-creatinine clearance ratio: in FHH it typically falls below 0.01, whereas primary hyperparathyroidism exceeds ~0.02. Because the receptor is globally insensitive, parathyroidectomy fails in FHH, so genetic testing spares patients unnecessary surgery. The mirror image is autosomal dominant hypocalcemia, caused by gain-of-function CASR variants that left-shift the set point, producing hypocalcemia with relative hypercalciuria; conventional calcium-and-vitamin-D treatment can worsen calciuria and trigger nephrocalcinosis, a risk a 2022 systematic review quantified in detail. Biallelic CASR inactivation causes neonatal severe hyperparathyroidism, a surgical emergency.

In acquired disease, secondary hyperparathyroidism of chronic kidney disease is marked by progressive CaSR and vitamin-D-receptor down-regulation in parathyroid tissue, which blunts the receptor's braking effect and fosters resistance to allosteric CaSR activators. Cancer adds a different dimension: CaSR is over-expressed in breast, prostate, and renal cancers, where the high-calcium bone-metastatic niche is trophic — CaSR drives PTHrP secretion, Rab27B-dependent cytokine release, and Gβγ-AKT-mTORC2 migration in breast models, while in colorectal cancer CaSR behaves more like a suppressor. A 2023 study linked higher CaSR expression in breast carcinoma to larger tumors, HER2 positivity, nodal involvement, and distant metastasis, supporting its use as a prognostic marker rather than a generic "calcium gene."

Figure 2. Pathophysiological effects of hypo- and hypercalcemia at the parathyroid glands, the kidneys and the skeleton. (Source: Höppner J, et al. 2022)